highly significantP < 0.001
The absolute decrease in adverse effects was highly significant with 3.2% and 4.9% (both P < 0.001) for the 1-year and 3-year endpoints, respectively, corresponding to 33.2% (95% CI, 26.6 to 41.9) and 25.0% (95% CI, 20.4 to 31.4) of relative reduction.